SARM
BMS-564929
SaveA non-steroidal selective androgen receptor modulator developed by Bristol-Myers Squibb, studied preclinically for androgen-deficiency conditions.
Quick verdict
An early pharmaceutical SARM candidate with limited public data. Development appears discontinued.
Evidence score
20/ 100
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Published preclinical data shows oral bioavailability and tissue selectivity in rats. The compound did not advance into publicly reported human efficacy trials.
Benefits
- Demonstrated oral bioavailability in preclinical models
- Tissue-selective AR binding in vitro
Dosage notes
No human dosing established.
Side effects
- Unknown in humans
- Likely hormonal axis suppression
Who should be cautious
Not approved for any clinical use. No publicly available human safety data.
What this page cannot tell you
Development status is unclear. All published results are from animal models.
Leaderboard scores
- Muscle25
Write a review
Sign in to write a review.